Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ClearPoint Neuro Inc (CLPT) vs Phillips 66 (PSX) Price & Performance

ClearPoint Neuro IncTrade
Phillips 66Trade

Price performance (Past 24H)

Key statistics

ClearPoint Neuro Inc vs Phillips 66 — how do they compare? ClearPoint Neuro Inc trades at $14.57 (market cap $454.21M), while Phillips 66 trades at $224.49 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 197.1× ClearPoint Neuro Inc's market cap, and Phillips 66 pays a 2.26% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.

CLPTPSX
Market Cap
$454.21M$89.52B
Sector
HealthEnergy
52-Week High
$29.60$224.36
52-Week Low
$8.66$120.04
Enterprise Value
$488.79M$105.99B
Dividend Yield
2.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.

The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.

Phillips 66

Phillips 66 (PSX) trades at $215.52, up 5.69% in the last session, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $208 and resistance at $219. Fundamentally, Q2 2026 EPS of $9.41 significantly beat estimates, driven by robust refining margins and high utilization rates. Recent news highlights the final investment decision for the $5 billion Western Gateway Pipeline joint venture, signaling growth in midstream operations.

Outlook remains positive with analyst consensus favoring Buy ratings (57%) and a $221.92 price target. Key opportunities include sustained refining strength and debt reduction, while risks involve volatile crude prices and geopolitical tensions affecting supply chains. Earnings growth and strategic projects underpin potential upside, but investors should monitor margin pressures and global energy dynamics.

Returns comparison

Trailing returns across standard periods

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT

About Phillips 66

Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.

Read more on PSX